secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOTRICITY INC. (BTCY)
CIK:        0001630113
Form:       8-K
Filed at:   2023-08-17T23:59:59+00:00
Accession:  0001493152-23-029242
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biotricity Q1 FY2024 revenue up 46.9% to $3.0M; net loss improves 28% to $3.6M
------------------------------------------------------------------------------

- Revenue $3.02M, up 46.9% YoY; recurring technology fees $2.8M, up 47% YoY.
- Gross margin improved to 63.5% from 59.6%; SG&A reduced 22% to $3.5M.
- Net loss improved 28% to $3.6M ($0.069 per share) from $5.0M ($0.098 per share).
- Customer retention ~98%; expanding sales network across 35 states with >2,500 cardiologists.
- Management focuses on path to profitability and AI development with Amazon and Google.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1630113/000149315223029242/0001493152-23-029242-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1630113/000149315223029242/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-029242

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer